BioVie (BIVI) stock

Worth $13.6MShares as of Nov 5

$1.27

-2.31%

As of Tuesday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score BIVI. It is too small for a fair Quality Score.

Healthcare · Biotech

Cash$7.7M, about 1 quarter at the last year's spendingOn Sep 30 · raised money since, not counted

Follow BIVI's news. Pro members can get an alert when BioVie files news, and see its trials, share raises, and its CEO's filings.

Get an alert when BIVI files newsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,168 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

Cash$7.7M, about 1 quarter at the last year's spendingOn Sep 30 · raised money since, not counted

What's next for BIVI, and how long its cash lasts

Cash runway Sep 30 balance sheet

About 1 quarter

$7.7M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 10 raises and their amounts, and the share count against a year ago.

Insiders

Chief Medical Officer Joseph M Palumbo bought 4,843 shares on Aug 28. 3 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Cuong V buys or sells

For Pro members: every trade, and Cuong V’s 4 filings and quotes.

Get an alert when BIVI files newsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

BIVI's latest filings

A shareholder vote8-K, filed Nov 10
Quarterly report10-Q, filed Nov 6
Prospectus for a sale of securities424B5, filed Nov 5

16 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why BIVI isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. BIVI is worth about $13.6M. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.